PECAM1 and colorectal cancer: A single-center randomized, double-blind placebo-controlled trial study showed that 14 daily doses of oral artesunate (200 mg) exerts antiproliferative properties in colorectal cancer via reducing Ki67, a protein that the up-regulation of which is associated with a poorer prognosis in colorectal cancer patients and increasing CD31 expression [234].